MerLion Pharmaceuticals Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 14

MerLion Pharmaceuticals General Information

Description

Developer of anti-bacterial drugs designed for combating serious bacterial infections. The company focuses on developing next-generation fluoroquinolone with properties that can treat different infections even within the intracellular compartments of infected macrophages, enabling healthcare providers to address antibiotic-resistant infections with high efficacy and safety.

Contact Information

Formerly Known As
Combinature Biopharm AG
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Robert-Rossle-Strasse 10
  • 13125 Berlin
  • Germany
+49 030
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • Robert-Rossle-Strasse 10
  • 13125 Berlin
  • Germany
+49 030

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MerLion Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 16-Apr-2024 Completed Generating Revenue
6. Later Stage VC 18-May-2021 Completed Generating Revenue
5. Secondary Transaction - Private 28-Apr-2022 Completed Clinical Trials - Phase 2
4. Grant 28-Jun-2017 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 13-Jul-2010 Completed Clinical Trials - Phase 1
2. Later Stage VC (Series B) 01-Mar-2007 $30M $43.5M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 30-Oct-2002 $13.5M $13.5M Completed Pre-Clinical Trials
To view MerLion Pharmaceuticals’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

MerLion Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-bacterial drugs designed for combating serious bacterial infections. The company focuses on developing
Drug Discovery
Berlin, Germany
10 As of 2022

New York, NY
 

Stockholm, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MerLion Pharmaceuticals Competitors (18)

One of MerLion Pharmaceuticals’s 18 competitors is Volastra, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Volastra Venture Capital-Backed New York, NY
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
Ona Therapeutics Venture Capital-Backed Barcelona, Spain
Melinta Therapeutics Private Equity-Backed Parsippany, NJ
Vicore Pharma Holding Formerly VC-backed Stockholm, Sweden
You’re viewing 5 of 18 competitors. Get the full list »

MerLion Pharmaceuticals Patents

MerLion Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-102015100068-A1 Finafloxacin for use in the treatment of harnway infections Inactive 06-Jan-2015
EP-3242667-A1 Finafloxacin for use in the treatment of urinary tract infections Active 06-Jan-2015
EP-3242667-B1 Finafloxacin for use in the treatment of urinary tract infections Active 06-Jan-2015
EP-3242667-C0 Finafloxacin for use in the treatment of urinary tract infections Active 06-Jan-2015
ES-2981965-T3 Finafloxacin for use in the treatment of urinary tract infections Active 06-Jan-2015 A61K31/5383
To view MerLion Pharmaceuticals’s complete patent history, request access »

MerLion Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MerLion Pharmaceuticals Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Denk Pharma Corporation Minority
Defense Threat Reduction Agency Government
Rosetta Capital (UK) Venture Capital Minority
Vi Partners Venture Capital Minority
Brandenburg Kapital Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

MerLion Pharmaceuticals Acquisitions (2)

MerLion Pharmaceuticals’s most recent deal was a Merger/Acquisition with Athelas (Drug Delivery). The deal was made on 21-Aug-2006.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Athelas (Drug Delivery) 21-Aug-2006 Merger/Acquisition Drug Discovery
Combinature Biopharm 21-Aug-2006 Merger/Acquisition Drug Discovery
To view MerLion Pharmaceuticals’s complete acquisitions history, request access »

MerLion Pharmaceuticals FAQs

  • When was MerLion Pharmaceuticals founded?

    MerLion Pharmaceuticals was founded in 2000.

  • Where is MerLion Pharmaceuticals headquartered?

    MerLion Pharmaceuticals is headquartered in Berlin, Germany.

  • What is the size of MerLion Pharmaceuticals?

    MerLion Pharmaceuticals has 10 total employees.

  • What industry is MerLion Pharmaceuticals in?

    MerLion Pharmaceuticals’s primary industry is Drug Discovery.

  • Is MerLion Pharmaceuticals a private or public company?

    MerLion Pharmaceuticals is a Private company.

  • What is MerLion Pharmaceuticals’s current revenue?

    The current revenue for MerLion Pharmaceuticals is .

  • How much funding has MerLion Pharmaceuticals raised over time?

    MerLion Pharmaceuticals has raised $50.5M.

  • Who are MerLion Pharmaceuticals’s investors?

    Denk Pharma, Defense Threat Reduction Agency, Rosetta Capital (UK), Vi Partners, and Brandenburg Kapital are 5 of 14 investors who have invested in MerLion Pharmaceuticals.

  • Who are MerLion Pharmaceuticals’s competitors?

    Volastra, Gesynta Pharma, Ona Therapeutics, Melinta Therapeutics, and Vicore Pharma Holding are some of the 18 competitors of MerLion Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process